In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

The stock's fall snapped a seven-day winning streak.

Shares of BIIB opened at $150.38 on Friday. The company has a market capitalization of $22.01 billion, a P/E ratio of 13.44, a P/E/G ratio of 1.51 and a beta of 0.01. Biogen Inc. has a one year ...

WM Technology Inc (MAPS) recently held its Q1 2025 earnings call, revealing substantial revenue growth and strategic advancements. According to InvestingPro analysis, the company appears ...

Pre-market: 4:36:52 am GMT-5 ...

Pre-Market: 5:58:06 a.m. EDT Loading Chart for BIIB ...